Cholesterol News and Research

RSS

Cholesterol is a waxy, fat-like substance made in the liver, and found in the blood and in all cells of the body. Cholesterol is important for good health and is needed for making cell walls, tissues, hormones, vitamin D, and bile acid.

What happens when more of your exercise is vigorous instead of moderate?

In a large UK Biobank analysis, a higher proportion of vigorous physical activity relative to total activity volume was associated with lower risks of eight major chronic diseases and all-cause mortality, even after accounting for overall activity volume. Device-based data suggested that activity intensity generally offered greater preventive potential than total volume alone across most outcomes.

31 Mar 2026

How swapping unhealthy foods can significantly reduce your heart risk

More than half of adults and about 60% of children in the U.S. have unhealthy diets, which can contribute to higher rates of health factors such as high blood pressure and obesity, and lead directly to poor health outcomes including deaths from cardiovascular disease and other chronic conditions, according to the American Heart Association.

31 Mar 2026

Measuring heart fat with AI improves cardiovascular risk prediction

Mayo Clinic research identified a powerful new way to improve the prediction of a patient's long-term cardiovascular disease risk by enhancing a routinely performed imaging test with artificial intelligence (AI).

30 Mar 2026

Community health fair promotes cancer awareness and preventive screenings

Ochsner Health welcomed Iberville Parish residents and families on Saturday, March 28 for the Iberville Parish Health Fair & Community Celebration, a no-cost community event focused on cancer awareness and prevention, and access to care close to home.

30 Mar 2026

AI eye exams accurately identify heart disease risk during routine visits

A new system that uses artificial intelligence (AI) to assess cardiovascular risk based on images of the eye captured during eye exams demonstrated strong correlation with a standard cardiovascular risk assessment, according to a study presented at the American College of Cardiology's Annual Scientific Session (ACC.26).

30 Mar 2026

Triglyceride-lowering drug olezarsen fails to reduce arterial plaque

Despite experiencing significant reductions in triglycerides, patients with triglycerides over 150 mg/dL and a high risk of atherosclerosis did not experience any significant change in the amount of non-calcified plaque in their coronary arteries after taking the triglyceride-lowering drug olezarsen, in a one-year sub-study presented at the American College of Cardiology's Annual Scientific Session.

30 Mar 2026

New clinical guideline adopts holistic approach to brain and heart health

A new brain–heart clinical practice guideline takes a holistic approach, integrating neurologic and mental health evidence with guidance for cardiovascular disease as many brain and heart conditions overlap and share similar risk factors.

30 Mar 2026

Nuclera launches GPCR-focused nanodisc panel to streamline membrane protein production

Nuclera, the biotechnology company enabling rapid access to high-quality proteins, today announced the launch of its nanodisc panel to support screening and scale-up of G-Protein Coupled Receptors (GPCRs).

From Nuclera 30 Mar 2026

Novel vFFR method performs similar to invasive coronary assessment

A novel, minimally invasive method of determining whether fatty deposits in a coronary artery are restricting blood flow to a patient's heart performed similarly to the standard, more-invasive procedure in a large multi-country European randomized trial presented at the American College of Cardiology's Annual Scientific Session (ACC.26).

29 Mar 2026

AI-based tool matches standard method for coronary blood flow assessment

A novel, minimally invasive computer software-based method that uses artificial intelligence to determine whether plaques in a coronary artery are restricting blood flow to the patient's heart performed similarly to the standard, more invasive wire-based procedure, according to a large international randomized trial presented at the American College of Cardiology's Annual Scientific Session (ACC.26).

29 Mar 2026

Angioplasty improves symptoms in chronic total coronary occlusion patients

In what is believed to be the first randomized placebo-controlled trial of its kind, patients with a chronic total blockage of a coronary artery who received a nonsurgical procedure to reopen the artery showed statistically significant reductions in chest pain and improvements in quality of life compared with patients who received a placebo procedure.

29 Mar 2026

Higher sugar intake raises gallstone risk in adults, study finds

A cross-sectional NHANES study of 8,975 U.S. adults found that higher total dietary sugar intake was associated with higher odds of gallstones, with each 100 g/day increase linked to a 41% rise after full adjustment. The findings suggest sugar intake may be a modifiable gallstone risk factor, but the study relied on self-reported gallstones and cannot establish causation.

29 Mar 2026

Intensive LDL cholesterol-lowering shows major benefits for heart disease patients

Using cholesterol-lowering medications more intensively to achieve a more aggressive target for low-density lipoprotein cholesterol (LDL-C) reduced the rate of major cardiovascular events by one-third among patients with atherosclerotic cardiovascular disease (ASCVD), according to a study presented at the American College of Cardiology's Annual Scientific Session (ACC.26).

28 Mar 2026

Evolocumab reduces cardiac events in high-risk diabetic patients

The cholesterol-lowering therapy evolocumab reduced the risk of major adverse cardiac events by nearly one-third among patients who had no known significant atherosclerosis and had diabetes, according to a study presented at the American College of Cardiology's Annual Scientific Session.

28 Mar 2026

Home-delivered DASH diet improves blood pressure and cholesterol outcomes

Black adults with high blood pressure who received dietitian counseling and home deliveries of groceries aligned with the DASH diet—meaning high in fruits, vegetables, whole grains, low-fat dairy, nuts, seeds, legumes and lean proteins—had an average overall reduction in systolic blood pressure of 7 mm Hg at three months overall and a 5 mm Hg reduction compared with participants who received only basic dietary guidance and a grocery stipend, according to a study presented at the American College of Cardiology's Annual Scientific Session (ACC.26).

28 Mar 2026

Intensive cholesterol‑lowering therapy reduces first major cardiac event in high‑risk patients with diabetes

Mass General Brigham researchers found that the intensive cholesterol‑lowering therapy evolocumab reduced the risk of a first major cardiovascular event in high‑risk patients who did not have known atherosclerosis (the build-up of plaque inside artery walls) but did have diabetes.

28 Mar 2026

Diverse biobank study links genetics to disease risk and treatment

A new study by UCLA Health published in Cell presents a major advancement in the future of personalized medicine by pinpointing new connections between people's genes, disease risk and medicine response by using a clinically well-characterized and diverse population-represented biobank.

27 Mar 2026

Updated heart guidelines urge earlier screening for high blood cholesterol

For the first time since 2018, a clinical guideline from the American College of Cardiology and the American Heart Association for screening and managing blood cholesterol levels has been updated and jointly published in the Journal of the American College of Cardiology and Circulation.

27 Mar 2026

New tool identifies harmful nutrition misinformation and evaluates potential risk

A new tool that not only identifies diet and nutrition misinformation online but also evaluates the content's risk for potential harm has been developed by a team of UCL researchers.

27 Mar 2026

Estradiol patches as effective as injections for locally advanced prostate cancer

Hormone patches are as good at controlling locally advanced prostate cancer as the injections typically used to deliver hormone therapy, according to the results of a large clinical trial led by UCL (University College London) researchers.

25 Mar 2026